U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C60H74N12O10.C2H4O2
Molecular Weight 1183.3583
Optical Activity UNSPECIFIED
Defined Stereocenters 7 / 7
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VELDOREOTIDE ACETATE

SMILES

C[C@]([H])([C@@]1([H])C(=N[C@@]([H])(Cc2ccccc2)C(=O)N(CCCC(=NCCCC(=N[C@@]([H])(Cc3ccccc3)C(=N[C@@]([H])(Cc4c[nH]c5ccccc45)C(=N[C@]([H])(Cc6c[nH]c7ccccc67)C(=N[C@@]([H])(CCCCN)C(=N1)O)O)O)O)O)O)CC(=N)O)O)O.CC(=O)O

InChI

InChIKey=OAISCAWXQQWLIC-NTYYTJCMSA-N
InChI=1S/C60H74N12O10.C2H4O2/c1-37(73)54-59(81)70-50(31-39-18-6-3-7-19-39)60(82)72(36-51(62)74)29-15-26-52(75)63-28-14-25-53(76)66-47(30-38-16-4-2-5-17-38)56(78)68-49(33-41-35-65-45-23-11-9-21-43(41)45)58(80)69-48(32-40-34-64-44-22-10-8-20-42(40)44)57(79)67-46(55(77)71-54)24-12-13-27-61;1-2(3)4/h2-11,16-23,34-35,37,46-50,54,64-65,73H,12-15,24-33,36,61H2,1H3,(H2,62,74)(H,63,75)(H,66,76)(H,67,79)(H,68,78)(H,69,80)(H,70,81)(H,71,77);1H3,(H,3,4)/t37-,46+,47+,48-,49+,50+,54+;/m1./s1

HIDE SMILES / InChI

Molecular Formula C60H74N12O10
Molecular Weight 1123.3063
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 7 / 7
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula C2H4O2
Molecular Weight 60.052
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Somatoprim (DG3173) is a heptapeptide somatostatin analog (SSA) that binds with high affinity to sstr2, sstr4 and sstr5 and shows a very low insulin suppression in contrast to other SSA. Initially developed by Ipsen, it is under active development by licensee Aspireo Pharmaceuticals, an Israeli company. In vitro as well as in vivo testing showed a dose-dependent GH lowering effect. Somatoprim has demonstrated a unique receptor binding and pharmacological profile which is differentiated from SSAs that are currently marketed or in clinical development. In particular, Somatoprim has shown an improved side effect profile with reduced adverse effects on the gastrointestinal tract and glucose metabolism. Furthermore, assessment of growth hormone secretion in cultured human somatotroph adenoma tissue treated with Somatoprim indicates that it has the potential to increase the response rate of acromegalic patients to SSA therapy. Somatoprim is currently in phase I/II of clinical development.

Approval Year

PubMed

PubMed

TitleDatePubMed
Pharmacotherapy: Somatoprim versus octreotide in acromegaly.
2011 Nov 29
A transplantable phosphorylation probe for direct assessment of G protein-coupled receptor activation.
2012
Emerging drugs for acromegaly.
2014 Mar
[Current and future therapy of acromegaly].
2016 Fall

Sample Use Guides

Acromegaly: octreotide and Somatoprim (DG3173). Eligible patients are to receive 300 ug octreotide as active comparator, followed by four ascending doses of 100 ug, 300 ug, 900 ug and 1800 ug DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
Route of Administration: Other
PTR-3173 suppressed GH release from both fetal pituitaries (maximal suppression of 54% with 10 nM) and cultures of GH-cell adenomas (35% suppression with 100 nM).
Substance Class Chemical
Created
by admin
on Sat Jun 26 06:56:11 UTC 2021
Edited
by admin
on Sat Jun 26 06:56:11 UTC 2021
Record UNII
9F2286627L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VELDOREOTIDE ACETATE
Common Name English
SOMATOPRIM ACETATE
Common Name English
COR-005 ACETATE
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 397713
Created by admin on Sat Jun 26 06:56:11 UTC 2021 , Edited by admin on Sat Jun 26 06:56:11 UTC 2021
EU-Orphan Drug EU/3/12/1075
Created by admin on Sat Jun 26 06:56:11 UTC 2021 , Edited by admin on Sat Jun 26 06:56:11 UTC 2021
Code System Code Type Description
FDA UNII
9F2286627L
Created by admin on Sat Jun 26 06:56:11 UTC 2021 , Edited by admin on Sat Jun 26 06:56:11 UTC 2021
PRIMARY
PUBCHEM
131634006
Created by admin on Sat Jun 26 06:56:11 UTC 2021 , Edited by admin on Sat Jun 26 06:56:11 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY